Abstract
The therapeutic effect of the α2-antagonist yohimbine in erectile dysfunction was studied in a double-blind placebo-controlled design. Thirty-one male patients underwent extensive clinical, urological, and psychiatric diagnosis and were dichotomically classified into an organic and a nonorganic subgroup. Following a 1-week placebo run-in period, patients were randomly assigned to a placebo or a verum group (yohimbine 15 mg daily) for a treatment period of 7 weeks. The Clinical Global Impression (CGI) scale was used as the primary efficacy parameter. Additionally, nocturnal penile tumescence and rigidity (NPTR) were measured. Global assessment of erectile function applying the CGI scale revealed, beyond a placebo effect in both organic and nonorganic patients, a therapeutic effect in the subgroup of nonorganic patients, with a significantly greater improvement in the yohimbine group compared to the placebo group. No superiority of yohimbine compared to placebo was found in the organic patients. These findings on the subjective level had no correlate in the NPTR recordings. The NPTR parameters were unchanged under yohimbine treatment in both the nonorganic and organic subgroup. No interrelation was found between subjective improvement and NPTR alterations. Polysomnographic control of the NPTR registrations ensured that the duration of REM sleep under treatment was not influenced.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Psychiatric Association (1987).Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., rev., APA, Washington, DC.
Benkert, O., Maier, W., and Holsboer, F. (1985). Multiaxial classification of male sexual dysfunction.Br. J. Psychiat. 146: 628–632.
Brindley, G. S. (1986). Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis.Br. J. Pharmacol. 87: 495–500.
Clark, J. T., Smith, E. R., and Davidson, J. M. (1984). Enhancement of sexual motivation in male rats by yohimbine.Science 225: 847–848.
Clark, J. T., Smith, E. R., and Davidson, J. M. (1985). Evidence for the modulation of sexual behavior by α-adrenoceptors in male rats.Neuroendocrinology 41: 36–43.
Condra, M., Morales A., Surridge, D. H., Owen, J. A., Marshall, P., and Fenemore, J. (1986). The unreliability of nocturnal penile tumescence recordings as an outcome measurement in the treatment of organic impotence.J. Urol. 135: 280–282.
Goldberg, M. R., and Robertson, D. (1983). Yohimbine: A pharmacological probe for study of the α2-adrenoreceptor.Pharmacol. Rev. 35: 143–180.
Guy, W. (1976).ECDEU Assessment Manual for Psychopharmacology, Revised, DHEW Publication (ADM), National Institute for Mental Health, Rockville, MD.
Krause, J., Herth, T., Maier, W., Steiger, A., Schöneich, S., and Benkert, O. (1991). An interdisciplinary study towards a multiaxial classification of male sexual dysfunction.Acta Psychiat. Scand. 84: 130–136.
Lancet. (1986). Yohimbine: Time for resurrection?Lancet 2: 1194–1195.
Meisler, A. W., and Carey, M. P. (1990). A critical review of nocturnal penile tumescence monitoring in the diagnosis of erectile dysfunction.J. Nerv. Men. Dis. 178: 78–89.
Morales, A., Condra, M. S., Owen, J. E., Fenemore, J., and Surridge D. H. (1988). Oral and transcutaneous pharmacologic agents in the treatment of impotence.Urol. Clin. N. Am. 15: 87–93.
Morales, A., Condra, M., Owen, J. A., Surridge, D. H., Fenemore, J., and Harris, C. (1987). Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial.J. Urol. 137: 1168–1172.
Morales, A., Surridge, D. H. C., Marshall, P. G., and Fenemore, J. (1982). Nonhormonal pharmacological treatment of organic impotence.J. Urol. 128: 45–47.
Peters, R. H., Koch P. C., and Blythe, B. L. (1988). Differential effects of yohimbine and naloxone on copulatory behaviors of male rats.Behav. Neurosci. 102: 559–564.
Rechtschaffen, A., and Kales, A. (1968).A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects, Public Health Service, U.S. Government Printing Office, Washington, DC.
Reid, K., Morales, A., Harris, C., Surridge, D. H. C., Condra, M., and Owen, J. (1987). Double-blind trial of yohimbine in treatment of psychogenic impotence.Lancet 1, 421–423.
Reynolds, C. F., Frank, E., Thase, M. E., Houck, P. R., Jennings, J. R., Howell, J. R., Lilienfeld, S. O., and Kupfer, D. J. (1988). Assessment of sexual function in depressed, impotent, and healthy men: factor analysis of a brief sexual function questionnaire for men.Psychiat. Res. 24: 231–250.
Riley, A. J., Goodman, R. E., Kellett, J. M., and Orr, R. (1989). Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy.Sex. Marital Ther. 4: 17–26.
Rosen, R. C., and Ashton, A. K. (1993). Prosexual drugs: Empirical status of the “New Aphrodisiacs.”Arch. Sex. Behav. 22: 521–543.
Schiavi, R. C. (1988). Nocturnal penile tumescence in the evaluation of erectile disorders: A critical review.J. Sex Marital Ther. 14: 83–95.
Segraves, R. T. (1989). Effects of psychotropic drugs on human erection and ejaculation.Arch. Gen. Psychiat. 46: 275–284.
Smith, E. R., and Davidson, J. M. (1990). Yohimbine attenuates aging-induced sexual deficiencies in male rats.Physiol. Behav. 47: 631–641.
Smith, E. R., Lee, R. L., Schnur, S. L., and Davidson, J. M. (1987). Alpha 2-adrenoceptor antagonists and male sexual behavior: I. Mating behavior.Physiol. Behav. 41: 7–14.
Sohn, M. H., Seeger, U., Sikora, R., and Jakse, G. (1993). Criteria for examiner-independent nocturnal penile tumescence and rigidity monitoring (NPTR): Correlations to invasive diagnostic methods.Int. J. Impotence Res. 5: 59–68.
Sonda, L. P., Mazo, R., and Chancellor, M. B. (1990). The role of yohimbine for the treatment of erectile impotence.J. Sex Marital Ther. 16: 15–21.
Steiger, A., and Benkert, O. (1989). Examination and treatment of sleep-related painful erections—A case report.Arch. Sex. Behav. 18: 263–267.
Steiger, A., Holsboer, F., and Benkert, O. (1987). Effects of brofaremine (CGP 11 305A), a short-acting, reversible, and selective inhibitor of MAO-A on sleep, nocturnal penile tumescence and nocturnal hormonal secretion in three healthy volunteers.Psychopharmacology 92: 110–114.
Susset, J. G., Tessier, C. D., Wincze, J., Bansal, S., Malhotra, C., and Schwacha, M. G. (1989). Effect of yohimbine hydrochloride on erectile impotence: A double-blind study.J. Urol. 141: 1360–1363.
Author information
Authors and Affiliations
Additional information
Study supported by Kali-Chemie GmbH, Hannover, Germany
Rights and permissions
About this article
Cite this article
Mann, K., Klingler, T., Noe, S. et al. Effects of yohimbine on sexual experiences and nocturnal penile tumescence and rigidity in erectile dysfunction. Arch Sex Behav 25, 1–16 (1996). https://doi.org/10.1007/BF02437904
Issue Date:
DOI: https://doi.org/10.1007/BF02437904